Sai Life Sciences reported strong Q1FY26 results, with revenue rising 77% YoY to ₹496 crore, driven by a 113% surge in its CDMO segment and a 38% growth in Discovery services. EBITDA soared 305% to ₹125 crore, improving margins to 25% from 11% last year. Net profit (PAT) stood at ₹60 crore, reversing a ₹13 crore loss in Q1FY25. The company also invested ₹134 crore in capex during the quarter, enhancing R&D and manufacturing infrastructure.
Operational highlights include the start of commercial operations at Bidar Unit IV (adding 91 KL capacity), launch of a new Peptide Research Center, and a 10,300 sq. ft. Biology facility in Hyderabad. It also initiated construction of a new Medicinal Chemistry block and a Process R&D Block, nearly doubling its R&D capacity.
CEO Krishna Kanumuri highlighted strong performance across business units and emphasized ongoing investments to support complex and emerging drug development needs. CFO Siva Chittor echoed optimism, citing operational efficiency, deeper global client engagement, and future readiness as key drivers of growth.
With a robust pipeline, expanding capabilities, and a growing scientific team, Sai Life Sciences is positioning itself as a trusted global CRDMO partner in advancing complex pharmaceutical innovation.
